BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11275367)

  • 1. Humanized anti-ganglioside GM2 antibody is effective to induce antibody-dependent cell-mediated cytotoxicity in mononuclear cells from lung cancer patients.
    Parajuli P; Yanagawa H; Hanibuchi M; Takeuchi E; Miki T; Yano S; Sone S
    Cancer Lett; 2001 Apr; 165(2):179-84. PubMed ID: 11275367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes.
    Hanibuchi M; Yano S; Nishioka Y; Yanagawa H; Sone S
    Jpn J Cancer Res; 1996 May; 87(5):497-504. PubMed ID: 8641987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody.
    Nakamura K; Hanibuchi M; Yano S; Tanaka Y; Fujino I; Inoue M; Takezawa T; Shitara K; Sone S; Hanai N
    Cancer Res; 1999 Oct; 59(20):5323-30. PubMed ID: 10537316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo.
    Fukumoto H; Nishio K; Ohta S; Hanai N; Fukuoka K; Ohe Y; Sugihara K; Kodama T; Saijo N
    Int J Cancer; 1999 Aug; 82(5):759-64. PubMed ID: 10417777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice.
    Hanibuchi M; Yano S; Nishioka Y; Yanagawa H; Kawano T; Sone S
    Int J Cancer; 1998 Nov; 78(4):480-5. PubMed ID: 9797137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant antibodies against ganglioside expressed on tumor cells.
    Hanai N; Nakamura K; Shitara K
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody.
    Nakamura K; Tanaka Y; Fujino I; Hirayama N; Shitara K; Hanai N
    Mol Immunol; 2000 Dec; 37(17):1035-46. PubMed ID: 11399321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of adriamycin resistance with chimeric anti-ganglioside GM2 antibody.
    Fukumoto H; Nishio K; Ohta S; Hanai N; Saijo N
    Int J Cancer; 1996 Sep; 67(5):676-80. PubMed ID: 8782657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human interferon-gamma enhances expression of ganglioside GM2 on human lung cancer cells and their susceptibility for antiganglioside GM2 monoclonal antibody-dependent cellular cytotoxicity.
    Hanibuchi M; Nishioka Y; Yanagawa H; Yano S; Parajuli P; Bando M; Sone S
    Oncol Res; 2000; 12(4):173-9. PubMed ID: 11341466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966.
    Hanibuchi M; Yano S; Nishioka Y; Yanagawa H; Miki T; Sone S
    Clin Exp Metastasis; 2000; 18(5):353-60. PubMed ID: 11467766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells.
    Yamada T; Bando H; Takeuchi S; Kita K; Li Q; Wang W; Akinaga S; Nishioka Y; Sone S; Yano S
    Cancer Sci; 2011 Dec; 102(12):2157-63. PubMed ID: 21895875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of multiorgan metastases of human lung cancer cells genetically engineered to produce cytokines and reversal using chimeric monoclonal antibodies in natural killer cell-depleted severe combined immunodeficient mice.
    Sone S; Yano S; Hanibuchi M; Nokihara H; Nishimura N; Miki T; Nishioka Y; Shinohara T
    Cancer Chemother Pharmacol; 1999; 43 Suppl():S26-31. PubMed ID: 10357555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
    Retter MW; Johnson JC; Peckham DW; Bannink JE; Bangur CS; Dresser K; Cai F; Foy TM; Fanger NA; Fanger GR; Woda B; Rock KL
    Cancer Res; 2005 Jul; 65(14):6425-34. PubMed ID: 16024647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivity of a mouse/human chimeric anti-GM2 antibody KM966 with brain tumors.
    Dohi T; Nakamura K; Hanai N; Taomoto K; Oshima M
    Anticancer Res; 1994; 14(6B):2577-81. PubMed ID: 7872684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
    Livingston PO; Hood C; Krug LM; Warren N; Kris MG; Brezicka T; Ragupathi G
    Cancer Immunol Immunother; 2005 Oct; 54(10):1018-25. PubMed ID: 15926079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
    Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin class switch of anti-ganglioside monoclonal antibody from IgM to IgG.
    Shitara K; Fujiwara K; Igarashi S; Ohta S; Furuya A; Nakamura K; Koike M; Hanai N
    J Immunol Methods; 1994 Feb; 169(1):83-92. PubMed ID: 8133075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
    Kurai J; Chikumi H; Hashimoto K; Yamaguchi K; Yamasaki A; Sako T; Touge H; Makino H; Takata M; Miyata M; Nakamoto M; Burioka N; Shimizu E
    Clin Cancer Res; 2007 Mar; 13(5):1552-61. PubMed ID: 17332301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions.
    Nakamura K; Tanaka Y; Shitara K; Hanai N
    Cancer Immunol Immunother; 2001 Jul; 50(5):275-84. PubMed ID: 11499811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.